The current challenge in developing early detection reagents for Parkinson’s disease (PD) is the difficulty in accurately detecting the disease. Through in-depth research and careful evaluation, Anbio has developed an effective method using real-time polymerase chain reaction (RT-PCR) for the early detection of PD.
Parkinson’s disease is a neurological disorder whose exact cause remains unknown. It is believed to be a combination of genetic and environmental factors. Currently, there’s no cure for PD. Years of research have shown that by the time patients exhibit typical symptoms of PD, a significant number of dopamine cells have already died. Intervening and treating at this stage cannot reverse the further deterioration of brain function.
As it progresses, patients face challenges with speech and movement, leading to a loss of independence. Hence, genetic testing for Parkinson’s is critical to understand an individual’s risk and ensure early detection. Identifying genetic mutations tied to PD empowers individuals to make informed health decisions. It also propels researchers towards crafting targeted therapies. Delving into these genetic foundations can also set the stage for tailored treatment plans, optimizing patient outcomes.1
Further reading: Anbio Launches New Handheld Analyzer for Rapid Testing
Research indicates that early-onset Parkinson’s disease has links to mutations in the glucocerebrosidase (GBA) and LRRK2 genes, with L444P, G2385R, and R1628P being the most prevalent pathogenic mutations. Anbio’s GBA L444P/LRRK2 R1628P/ LRRK2 G2385R Gene Mutations Polymorphism Test Kit is a Real-time Polymerase Chain Reaction product that can qualitatively detect these three specific polymorphisms in the GBA and LRRK2 genes. The invention aims to provide a detection kit for GBA and LRRK2 gene polymorphisms that can identify these polymorphisms quickly, accurately, and with high throughput.
- High Sensitivity and Specificity – Uses highly specific Taq enzyme and fluorescent probes, effectively enhancing the specificity of detection.
- High Accuracy – Internal and multiple positive controls are used for quality control, eliminating false negatives and positives.
- Simple and Fast – Detection of three GBA and LRRK2 gene polymorphisms can be completed within 117 minutes. The operation process is straightforward, and the results are easy to interpret, objective, and reliable.
The product has a high degree of accuracy, sensitivity, and specificity in detecting the three listed genetic mutations compared to other similar products in the market. The detection results of Anbio’s GBA L444P/LRRK2 R1628P/ LRRK2 G2385R Gene Mutations Polymorphism Test Kit are of great significance for the discovery of the pathogenesis of Parkinson’s disease and the formulation of treatment plans.
Featured image: L444P/LRRK2 R1628P/ LRRK2 G2385R Gene Mutations Polymorphism Test Kit. Photo: Anbio
References: 1. Cook L, Schulze J, Kopil C, et al. Genetic Testing for Parkinson Disease: Are We Ready?. Neurol Clin Pract. 2021;11(1):69-77. doi:10.1212/CPJ.0000000000000831